Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: docetaxel
Drug: carboplatin

First Posted Date: 2007-08-24

Last Posted Date: 2011-08-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 260

Registration Number: NCT00520676

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan

Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Pemetrexed
Drug: Dexamethasone

First Posted Date: 2007-07-27

Last Posted Date: 2011-09-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT00507858

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

ZD6474(Vandetanib) + Alimta Combo Study

Phase 1

Completed

Conditions: Carcinoma
Non-Small Cell Lung
Lung Cancer

Interventions: Drug: ZD6474 (vandetanib) 100mg
Drug: pemetrexed
Drug: ZD6474 (vandetanib) 300mg

First Posted Date: 2007-07-25

Last Posted Date: 2016-08-25

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 21

Registration Number: NCT00506051

A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumor

First Posted Date: 2007-07-17

Last Posted Date: 2011-07-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 104

Registration Number: NCT00502567

Locations: 🇺🇸
Research Site, Nashville, Tennessee, United States

An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed

Completed

Conditions: Lung Neoplasms

Interventions: Drug: Pemetrexed

First Posted Date: 2007-07-09

Last Posted Date: 2012-05-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 434

Registration Number: NCT00497770

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico

Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC)

Phase 2

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: carboplatin
Procedure: radiotherapy

First Posted Date: 2007-06-29

Last Posted Date: 2009-11-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 4

Registration Number: NCT00494026

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wolverhampton, West Midlands, United Kingdom

Pemetrexed Plus Gemcitabine in Renal Cell Cancer

Phase 2

Terminated

Conditions: Renal Cell Carcinoma

Interventions: Drug: Pemetrexed
Drug: Gemcitabine

First Posted Date: 2007-06-25

Last Posted Date: 2013-04-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00491075

Locations: 🇺🇸
UT MD . Anderson Cancer Center, Houston, Texas, United States

Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic

Phase 2

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2007-06-22

Last Posted Date: 2007-06-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 52

Registration Number: NCT00490373

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany

Trial of Pemetrexed or Pemetrexed With Gemcitabine for Patients With Advanced Lung Cancer Who Are Not Eligible for Platinum-Based Chemotherapy and Have Not Previously Been Treated With Chemotherapy

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2007-06-22

Last Posted Date: 2007-06-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 91

Registration Number: NCT00489983

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom

A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer

Phase 1

Completed

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: carboplatin
Drug: cisplatin
Radiation: radiation therapy

First Posted Date: 2007-06-04

Last Posted Date: 2012-11-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 120

Registration Number: NCT00482014

Locations: 🇮🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy